XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $1.85M invested in XTL Biopharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 3 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
7% less capital invested
Capital invested by funds: $2M → $1.85M (-$149K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$63.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.25K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$504 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $1.67M | -$63.7K | -1,896 | -3% |
|
2
Invesco
Atlanta,
Georgia
| $183K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $1K | -$2.25K | -67 | -79% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| – | -$504 | -15 | -75% |
|
XTLB Hedge Fund Activity: Q4 2015 in Review
4 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2015, worth a combined $1.85M — down 7.4% from $2M a quarter earlier.
Fund positioning in XTLB was balanced in Q4 2015: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.
The largest seller was Sabby Management, cutting an estimated $63.7K.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $1.85M of XTL Biopharmaceuticals stock for Q4 2015, down 7.4% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q4 2015 and 0 closed out.
- The largest XTL Biopharmaceuticals seller in Q4 2015 was Sabby Management, an estimated $63.7K sold.
Based on aggregated 13F filings for Q4 2015.